Skip to main content
. 2022 Mar 30;12(4):851. doi: 10.3390/diagnostics12040851

Table 3.

Summary of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT.

Patient No. Tumor Type Tumor Size Qualitative PET
Uptake
SUVmax SUVmean
PET10 PET1h PET2h PET10 PET1h PET2h
1 NEN 4.4 cm Heterogeneous 4.53 4.55 5.70 2.58 2.37 2.93
2 NEN 4.9 cm Heterogeneous 10.36 17.70 14.32 5.31 8.74 7.73
3 NEN 4.4 cm Heterogeneous 7.85 8.77 15.35 4.10 4.48 7.86
4 BC 6 cm Heterogeneous 6.18 8.75 10.53 3.26 4.52 5.44
5 NEN 16 cm * Heterogeneous 7.39 9.39 8.83 2.93 3.2 3.15
6 BC 1.1 cm Homogeneous 4.88 7.15 8.02 4.59 6.75 6.79
7 BC 1.4 cm Homogeneous 3.05 2.29 2.66 1.67 1.30 1.94
8 BC 1.8 cm Homogeneous 7.09 8.40 7.10 4.18 4.70 4.04
9 BC 0.9 cm Homogeneous 4.24 4.99 4.45 2.36 2.54 2.58
10 NEN 10 cm Heterogeneous 5.90 7.58 5.80 3.27 3.69 3.05

Readouts of primary tumor SUVmax and SUVmean for all patients at all time points. Tumor size is based on the largest diameter of primary tumor on CT. * SUVmax/SUVmean values and tumor size of liver metastasis as location of primary neuroendocrine tumor was unknown. BC: breast cancer. NEN: neuroendocrine neoplasm PET10: PET 10 min after injection. PET1h: PET 1 h after injection. PET2h: PET 2 h after injection.